All drug pricing articles – Page 2
-
Business
India backs off drug pricing controls
Current price caps will stand, but rules on how new caps can be imposed are being tightened
-
Business
Review says cheaper drug is safe for eye disease
Cochrane collaboration says side effects of expensive Lucentis and off-label Avastin are similar
-
BusinessPrice caps provoke lawsuits from Indian pharma industry
New government controls on cardiovascular and diabetes drugs challenged by industry lobby groups
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Business
Drug spending to hit $1.2tn in 2016
Growth is expected to bottom out at 3–4% for 2012 and then rise to 5–7% for 2016
- Previous Page
- Page1
- Page2
- Next Page